$AUPH News

TD Cowen Maintains Buy on Aurinia Pharmaceuticals, Raises Price Target to $18

Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside

Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback

Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain

AUPH Stock Rallies 6% After-Hours — Here’s Why

Aurinia Settles Patent Litigation with Teva

Aurinia Settles Teva Patent Litigation, Protecting Voclosporin Exclusivity In U.S. Until December 2036 And Affirming Validity Of Key Patents Through 2037

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

RBC Capital Maintains Sector Perform on Aurinia Pharmaceuticals, Raises Price Target to $16

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals Affirms FY2026 Sales Guidance of $315.000M-$325.000M vs $323.065M Est

Aurinia Pharmaceuticals Q2 EPS $0.28 Beats $0.24 Estimate, Sales $83.220M Beat $79.357M Estimate

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Aurinia (AUPH) Upgraded to Strong Buy: Here's Why

Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?